Cardio Intelligence Raises Series B Funding
Cardio Intelligence, a company dedicated to developing AI-powered medical devices to assist cardiologists, has successfully completed a Series B funding round. The round was led by Altmos Investment, with participation from Shin Nippon Biomedical Laboratories, Tokai Tokyo Investment, and Iwagin Business Creation Capital. The company has not disclosed the total amount raised.
Advancing AI Medical Devices
Cardio Intelligence is focused on alleviating the shortage of cardiology specialists by making electrocardiogram (ECG) testing more accessible. Their flagship product, the SmartRobin AI Series, uses artificial intelligence to automatically analyze long-term ECG results, detecting conditions like atrial fibrillation with high accuracy. This tool enables even non-specialist medical staff to identify arrhythmias quickly and efficiently.
Strategic Use of Funds
The newly acquired funds will be directed towards further product development and the introduction of new medical devices. Cardio Intelligence plans to expand its product lineup, including the rollout of devices like the SmartPAFin Series, which detects potential risks for paroxysmal atrial fibrillation. Additionally, the company aims to bolster its internal structures to support these initiatives.
Leadership and Global Expansion
The company is also undergoing a significant management restructuring. Yuichi Tamura, the founder and current Representative Director, will share leadership duties with Shigemasa Sasaki, who brings extensive experience in the life sciences sector. This dual leadership model is expected to facilitate Cardio Intelligence's efforts to expand its presence internationally.
Conclusion
With the backing of key investors, Cardio Intelligence is poised to enhance its AI-driven solutions for the medical field and pursue global expansion. The company's innovative approach to ECG analysis and commitment to addressing the cardiologist shortage highlights its potential to impact healthcare positively.